Introduction
In Canada, the incidence and prevalence of heart failure (HF) is rising. Approximately 600,000 patients are living with HF and 50,000 more are diagnosed each year. The burden of HF is significant. Mortality rate is high (20% in 1 year, 50% in 5 years), and morbidity, such as hospitalizations, is frequent. The cost to the health care system is significant at $2.8 billion per year. 1 In 2017, the Canadian Cardiovascular Society published a comprehensive update to the heart failure management guidelines. 2 These guidelines aimed to provide broad recommendations across the spectrum of HF. The full document can be viewed at www.onlinecjc.ca/article/ S0828-282X(17)30973-X/pdf. In this summary of the guidelines, we aim to highlight the recommendations that are most relevant to the practising pharmacist, with a focus on chronic HF with reduced ejection fraction since this subgroup of HF has the most evidence for pharmacotherapy.
Pharmacist roles in heart failure
Heart failure is a complex disease, requiring polypharmacy and often involving multiple comorbidities. Due to these complexities and the fact that pharmacists are the most easily accessible and frequently seen health care provider, pharmacists can play a significant role in the management of HF. There is a large body of evidence supporting the role of the pharmacist specifically in caring for patients with HF. The following activities can be performed by pharmacists in multiple settings when caring for patients with HF.
Medication reconciliation/medication reviews
• Patients with HF are on multiple medications and changes are made frequently; therefore, medication reconciliation is very important, especially at transfers of care and discharges back to community. Medication review and reconciliation can increase adherence, reduce readmissions and reduce cost to the system.
3,4
Promotion of medication adherence • Being aware of factors that could influence adherence, such as being a visible minority, living alone, having multiple comorbidities and/or depression, 5 can help identify patients who may require more interventions from the pharmacist. Interventions include clarifying instructions on labels, intensifying education and closer follow-up.
• Discharge counselling and education after discharge have also been shown to improve adherence in patients with HF.
6-8

Education
• Pharmacists should educate their patients on medications, management of side effects, self-monitoring, symptom management, dietary modifications and lifestyle modifications in HF. Many of these points will be covered in this summary of the heart failure guidelines.
• Pharmacist education of HF patients has been shown to reduce readmissions for heart failure, decrease length of stay in hospital, 9 improve survival 10 and improve symptoms.
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Medication management
• Heart failure treatment requires multiple medications with a large potential for interactions, side effects and changes.
Pharmacists are perfectly positioned to help with the initiation, titration and • Transitions in care: After discharge, many HF patients require close follow-up, and pharmacists can be a resource before they have their next follow-up appointment. Pharmacist-led bridge clinics postdischarge have been found to decrease mortality in HF patients.
20
Advocacy and public health • Vaccination against influenza and pneumococcal disease of these high-risk patients is also a key role that pharmacists can play in caring for these patients.
Definition of heart failure
Heart failure is a complex clinical syndrome in which abnormal heart function results in, or increases the subsequent risk of, clinical signs and symptoms of reduced cardiac output and/or pulmonary or systemic congestion at rest or with stress. Chronic HF refers to the persistent and progressive state of HF, and acute HF is a gradual or rapid change in signs and symptoms. Historically, left ventricular systolic dysfunction has been the major focus, but the syndrome of HF can result from a variety of conditions relating to both the structure (e.g., left or right sided, valvular, etc.) and function of the heart. New terminology has arisen to help describe different HF manifestations based on left ventricular (LV) function (Table 1) . This terminology helps determine the approach to medical management for these patients.
Those with an ejection fraction (EF) that is <40% with current or previous signs and symptoms of heart failure are referred to as having heart failure with reduced ejection fraction (HFrEF). This was previously termed systolic dysfunction. It should also be noted that patients may have an improvement or normalization of EF after medical treatment, but they would still retain their original classification of HFrEF but may also be referred to as having heart failure with improved EF (HFiEF).
Those with an EF >50% with current or previous signs and symptoms of HF are referred to as having heart failure with preserved ejection fraction (HFpEF). This was previously termed diastolic dysfunction. There is also a small subgroup that has an EF between 41% and 49%, and this is called heart failure with midrange ejection fraction (HFmEF). This group has been poorly studied.
This article includes details on how to initiate medications, which side effects are most common and how to deal with them, potential interactions that can occur with multiple medications, monitoring parameters when uptitrating and how medications can interact with different disease states.
Signs and symptoms
Although the causes of HF can be different, the clinical presentation results in similar signs and symptoms of reduced cardiac output and/or PRACTICE GUIDELINES fluid overload (Table 2 ). In addition to signs and symptoms, evaluation of functional capacity is also used to assess the degree of patient disability. The New York Heart Association (NYHA) functional classification (Table 3 ) is a common, practical tool used to describe the severity of patients' symptoms. This classification is also frequently used to define HF populations in clinical trials. Pharmacists should be familiar with these and use them in their patient assessments.
Diagnosis
While symptoms such as edema, fatigue and dyspnea are typical manifestations of HF, atypical presentations can occur, and other conditions may have similar symptoms. Therefore, in addition to symptoms, a thorough clinical history and physical examination, along with other investigations, are performed to help rule in or rule out HF. These investigations may include a chest X-ray, echocardiogram, lab work (such as thyroid function, renal function) and natriuretic peptides. Subsequently, all patients with suspected HF should undergo diagnostic imaging to assess the structure and function of the heart. It is recommended that an echocardiogram be performed in all patients to determine left ventricular ejection fraction (among other parameters); however, other modalities may also be used to help assess and determine the specific etiology of HF. The specific approaches to identifying the most common etiologies of HF can be found in the full guideline document.
Prevention
It is recommended that all patients have a clinical assessment to identify known or potential risk factors for the development of HF. Conventional risk factors for cardiovascular disease, such as hypertension, diabetes, obesity, smoking and dyslipidemia, overlap with specific risk factors attributed to the development of HF. Identification and modification of risk factors is key to the prevention of HF. Appendix 1 (available at www.cpjournal.ca) lists additional risk markers for the development of HF. 
Pharmacological treatment of HF
The overall goals of therapy in the treatment of HF include improving survival, reducing hospitalization, increasing functional capacity, mitigating symptoms and ultimately improving quality of life.
Heart failure with preserved ejection fraction (HFpEF)
Much of the clinical trial data pertaining to the treatment of HF with pharmacotherapy has focused on HFrEF. While there are a few studies that have looked at the treatment of HF patients with preserved ejection fraction (HFpEF) with similar agents used in HFrEF, overall results have generally been neutral, and hence recommendations are mostly aimed at identifying and treating underlying/predisposing factors (such as hypertension) and controlling symptoms of congestion with diuretics as required.
Heart failure with reduced ejection fraction (HFrEF)
The overall approach to pharmacotherapy has significantly changed in the 2017 guidelines. The last major update to the overall approach of pharmacotherapy occurred in 2012, and several changes incorporating new evidence over the past 5 years have been made. Additionally, new agents used in the treatment of HFrEF have entered the Canadian market (Table 4 ). Figure 1 summarizes the treatment recommendations. Described below are highlighted key recommendations, supporting evidence and considerations when applying these to the individual patient with HFrEF. Tables 4 to 8 
Why the change:
• Previous iterations of the guidelines recommended initiating dual therapy with ACEI/ARB and BB and only adding an MRA if the patient remained symptomatic with very specific criteria. The 2017 guidelines aimed to simplify the approach to the majority of patients with HFrEF and also to account for data highlighting MRA underutilization.
• Key clinical trials:
There are no new clinical trials affecting this recommendation.
| |
The EMPHASIS trial (2012) showed that eplerenone (compared to placebo) decreased the risk of cardiovascular (CV) deaths and hospitalizations due to heart failure in patients with an EF ≤35% and NYHA class II symptoms in addition to good medical management (ACEI/ARB and BB) with a recent CV hospitalization or elevated brain natriuretic peptide (BNP).
This data adds to the RALES trial (1999) data and provides evidence that MRAs improve HF outcomes across the spectrum of patients with HFrEF (NYHA classes II-IV). 22 How to apply:
• 
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target doses of ACEI/ARB do not need to be achieved prior to initiating MRAs.
• The goal is to titrate and monitor regularly to achieve target doses (Table 4) or maximally tolerated doses within 6 months.
• Considerations when starting each class and what to monitor are outlined in Table 5 .
In patients who continue to be symptomatic after optimization of triple therapy, consider switching the ACEI/ARB to an angiotensin receptor neprilysin inhibitor (ARNI).
Why the change:
• Sacubitril/valsartan is an ARNI and currently is the only agent of its class available on the Canadian market. Sacubitril inhibits the neprilysin enzyme, resulting in increased natriuretic peptides. Natriuretic peptides promote diuresis, vasodilation, aldosterone suppression and inhibit fibrosis. Use of a neprilysin inhibitor is aimed at augmenting the beneficial physiological neurohormonal effects that occur in HF, which is in contrast to other agents used in HFrEF, which inhibit the deleterious neurohormonal effects of HF.
There are no new clinical trials affecting this recommendation; however, the agent entered the Canadian market in 2015.
| |
The PARADIGM-HF (2014) was a landmark trial comparing sacubitril/ valsartan to enalapril in patients with NYHA class II to IV symptoms, left ventricular ejection fraction (LVEF) ≤40% and a BNP ≥150 pg/mL or N-Terminal Prohormone B-type Natriuretic Peptide (NT-ProBNP) ≥600 pg/mL (or if they were hospitalized in the last year for HF, a BNP ≥ 100 pg/mL or NT-ProBNP ≥400 pg/mL). 23  Patients were eligible for study inclusion if they were on a moderate-dose ACEI/ARB (equivalent to enalapril 10 mg) and BB therapy for at least 4 weeks. Therapy with MRA was recommended but not required. How to apply:
• Table 6 provides a suggested initial dose depending on the patient's prior ACEI or ARB dose.
• Switching between agents needs some consideration.
| | ACEI to/from ARNI:  For patients on an ACEI, there should be at least a 36-hour washout period prior to starting the ARNI. A washout period is required to decrease the risk of angioedema.
| | ARB to/from ARNI:  A washout period is not required.
• Due to the inclusion criteria of an elevated BNP/NT-ProBNP in the PARADIGM-HF trial, certain jurisdictions require a BNP/ NT-ProBNP level to determine eligibility for drug coverage.
• Compared to enalapril, patients on sacubitril/valsartan experienced more hypotension and nonserious angioedema. However, they experienced less renal impairment, hyperkalemia, cough and discontinuations due to adverse events.
Blood pressure and signs and symptoms of hypotension should be monitored more closely when switching agents.
• ARNIs promote natriuresis, and therefore reassessment of diuretic dose should be considered upon initiation and up-titration.
In patients who continue to be symptomatic after optimization of triple therapy, who are in sinus rhythm with a resting heart rate >70 bpm and have had a HF hospitalization within the past 12 months, consideration should be given to the addition of ivabradine.
PRACTICE GUIDELINES
• Previous trials of BBs in HF have shown a correlation between lower heart rate and improved HF outcomes. It is hypothesized that perhaps the beneficial effects of BBs in HF are related to a reduced heart rate, which allows for better filling and contraction of the ventricles. Ivabradine selectively inhibits the I f current (or funny channel) in the sinus node, which slows depolarization, decreasing heart rate and prolonging diastolic time. This, in turn, increases stroke volume while still preserving myocardial contractility and relaxation, with no direct effect on blood pressure.
• Ivabradine is the first of its class and currently the only agent of its class available on the Canadian market.
• Key clinical trial:
There are no new clinical trials affecting this recommendation; however, ivabradine entered the Canadian market in 2017.
| |
The SHIFT trial (2010) compared ivabradine to placebo in patients with LVEF ≤35%, NYHA class II to IV symptoms, on good medical management (ACEI/ARB + BB ± MRA), hospitalized for HF within the last year and in sinus rhythm with a heart rate >70 bpm. 24  Ivabradine decreased the primary outcome (CV death and HF admission) by 18%, which was largely driven by hospital admission for worsening HF (NNT = 20 in 1.9 years).
How to apply:
• Every effort should be made to achieve target/maximum tolerated dose of BB before initiating ivabradine. Continue the BB when starting ivabradine.
• Start ivabradine at 5 mg twice a day, but consider the lower dose of 2.5 mg twice a day for the elderly or those with a history of conduction defects.
• Adjust ivabradine every 2 weeks to target HR of 50 to 60 bpm (see Table 7 ). Unlike BBs, there is no target dose.
• A subgroup analysis showed that the primary composite endpoint did not reach significance for patients with a baseline HR <77 bpm; therefore, regulatory bodies have approved the use of ivabradine in minimum heart rates ranging from 70 to 77 bpm. Health Canada's official indication is at a HR above 77 bpm.
• Symptomatic bradycardia and visual anomalies (phosphenes) occurred more frequently in the ivabradine group compared to the placebo group.
For symptomatic bradycardia, dose adjustments or discontinuation may be required (see Table 8 ).
Patients experiencing phosphenes should be cautioned about driving, especially at night. Phosphenes appear to be a transient side effect.
Combination of ACEI and ARB is no longer recommended.
Why the change:
• While there is a small benefit to combination ACEI and ARB in HF (mainly HF hospitalizations), other data indicate that the combination is associated with high rates of hypotension, hyperkalemia and renal dysfunction, pushing the risks to outweigh the benefits.
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• Given newer, more robust evidence for the benefits of adding an MRA and an ARNI, there is now little role for combination ACEI and ARB therapy.
How to apply:
• ACEI and ARB combination therapy should be discontinued and optimization of other guideline medications should be pursued according to the treatment algorithm. ISDN) and digoxin may still be considered but only in those who continue to be NYHA classes III to IV after all the above is tried.
Hydralazine with isosorbide dinitrate (H-
H-ISDN may be also considered in those who cannot tolerate ACEI/ARB/ARNI due to renal dysfunction.
Why the change:
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• With the arrival of new therapies and newer evidence, these medications offer minimal benefit in comparison to contemporary therapy. They are now considered last line after all other therapies have been tried if a patient continues to be severely symptomatic.
• These medications are added in addition to the other medications, except for in the case of substituting the ACEI/ARB/ARNI with H-ISDN for those who cannot tolerate ACEI/ARB/ARNI: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BP, blood pressure; HR, heart rate; K, potassium; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SBP, systolic blood pressure; BID, twice daily; bpm, beats per minute; q, every; SCr, serum creatinine. beta blockers -Should start at very low doses and titrate slowly to prevent decompensation or worsening of HF initially.
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-Those in NYHA classes I to II can be safely initiated by a nonspecialist physician. For NYHA classes III to IV, a BB should be initiated by a specialist in HF management and have close follow-up.
-In reactive airway disease, use a selective BB cautiously (e.g., bisoprolol or metoprolol).
-Reassess the need for other AV nodal blocking drugs used in combination (e.g., digoxin, amiodarone). If heart block is present, these may need to be minimized or stopped.
Heart rate and blood pressure -Consider a dose reduction if HR less than 50.
-If the patient has a low HR (HR 50-60) but is asymptomatic, there is no need to decrease dose. -Carvedilol, due to its α-1 blockade, will decrease blood pressure more than a beta-selective BB. If low BP is an issue, consider using a beta-selective BB. Fluid retention -Transient fluid retention can occur when increasing BB and patient may require a diuretic dose change.
(continued)
Drug
Considerations when starting Monitoring
Mra -Usually started after ACEI/ARB and BB have been introduced (but do not have to be at target doses prior to MRA initiation).
renal function and electrolytes -Monitor K+ and SCr 2 to 3 days after initiation, then 1 week after initiation. Check monthly ×3 months and then every 3 months thereafter. More frequent monitoring may be required in acute illness and those at high risk (DM, CKD, older). Hormonal side effects -Eplerenone, a more selective mineralocorticoid receptor antagonist, can be considered in those experiencing hormonerelated side effects (e.g., gynecomastia [9%], impotence, postmenopausal bleeding) from spironolactone.
arNi -Consider for patients who continue to be symptomatic (NYHA II symptoms or greater) despite being on triple therapy.
-Avoid in patients who have a K >5.2 mmol/L, eGFR <30 mL/min and symptomatic hypotension with a systolic BP <100 mmHg (PARADIGM-HF exclusion criteria).
Side effects and tolerability similar to aCei/arb
If patient has angioedema to ACEI or ARB, ARNI is contraindicated. renal function and electrolytes Monitor SCr and K+ 1 week after initiation or dose increase; after dose stabilization, monitor every 3 months. blood pressure ARNI can have more of a hypotensive effect compared to ACEI/ ARBs. i f inhibitor -Consider for patients who continue to be symptomatic (NYHA II symptoms or greater) despite being on appropriate doses of triple therapy and have a heart rate >70 bpm.
-Because ivabradine works on the SA node, the patient has to be in normal sinus rhythm (e.g., cannot have atrial fibrillation, sick sinus syndrome without pacemaker or pacemaker dependence).
-Patient should not be in acute decompensated HF or have a BP <90/50 mmHg.
Heart rate
Both ivabradine and BB will decrease HR. BB doses are optimized to target doses or maximally tolerated doses prior to starting ivabradine, so ivabradine is intended to further decrease HR to a target of 50 to 60 bpm. Monitoring HR and adjusting the ivabradine dose every 2 weeks may be required.
-Ivabradine has no adverse effect on blood pressure in stable ambulatory patients. interactions -Contraindicated with strong CYP3A4 inhibitors. electrolytes and kidney function -Monitor SCr and electrolytes 2 to 3 days, then 1 week after initiation and dose changes. blood pressure Weight -Daily morning weights should be monitored in patients with HF with fluid retention or congestion that is not easily controlled with diuretics or in patients with significant renal dysfunction.
Vasodilators
-Monitor weight more closely in unstable or frail patients: rapid weight gain (1.5-2 kg) should prompt a rapid medical visit. Symptoms -Diuretics are titrated to symptom relief. When euvolemia is achieved, dosing is titrated to the minimum effective dose to maintain euvolemia, which may include no diuretic at all.
-Some patients may be managed with a diuretic as needed and given parameters as to when the diuretic should be taken (e.g., take 20 mg of furosemide when >1 kg gained in 3 days).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; BB, beta-blocker; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HFrEF, having heart failure with reduced ejection fraction; ISDN, isosorbide dinitrate; K, potassium; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; RAAS, renin-angiotensin-aldosterone system; SA, sinoatrial; SCr, serum creatinine. 
Dealing with general side effects
Side effects can be common for patients with HF due to the prevalence of multiple comorbidities and medications. Below are ways to manage some of the most common side effects:
Hypotension
• If a patient is experiencing symptomatic hypotension (systolic blood pressure [SBP] <100 mmHg + symptoms of hypotension), reevaluate other antihypertensives without mortality benefit in HF and decrease/discontinue those agents before altering guideline-directed medical therapy (GDMT). Reassessment of diuretic doses should also be done.
• Try separating or staggering administration of drugs that lower BP (e.g., BB in the morning and ACEI/ARB in the evening) if patient has symptomatic hypotension.
• Patients with HF may have low blood pressure due to the reduced ejection fraction. This should not be an indication to lower doses of GDMT unless the patient is symptomatic and other strategies (such as the ones listed above) have been tried.
Hyperkalemia due to reninangiotensin-aldosterone system inhibitors
• For all instances of hyperkalemia: 
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• For more details on the management of hyperkalemia, please refer to the full Canadian Cardiovascular Society (CCS) 2017 guidelines, Table 13 .
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Renal dysfunction due to reninangiotensin-aldosterone inhibitors
• An increase in SCr or decrease in estimated GFR (eGFR) of up to 30% is not unexpected when an ACEI/ARB is introduced; if the increase stabilizes at 30%, there is no immediate need to decrease the drug dose, but closer long-term monitoring might be required.
• Consider concomitant medications that can also worsen renal function (e.g., NSAIDs, COX-2 inhibitors, SGLT-2 inhibitors).
• Consider volume status. Volume depletion or dehydration due to diuretics can worsen renal function. Fluid overload from HF can also decrease kidney perfusion and hence increase SCr. Look at the whole clinical picture.
• If the SCr increases more than 30%, a decreased dose or rechallenge when the patient is more stable may be required. If the patient still experiences significant renal dysfunction, consider the combination of hydralazine and ISDN in place of the reninangiotensin-aldosterone (RAAS) agent.
Not recommended
Statins, antiplatelets and anticoagulation are not recommended specifically for HFrEF unless there is another indication present. Antiinflammatories, calcium channel blockers (except amlodipine) and anti-arrhythmics (except amiodarone) should be avoided (Appendix 2). Pharmacists should routinely inquire about NSAID/COX-2 inhibitor use, especially those available for self-selection over the counter. These agents promote sodium and water retention, worsening renal function (especially in combination with a RAAS inhibitor), elevate blood pressure and have been shown to increase CV events and worsen HF.
Considerations with other disease states and drugs
Nonpharmacological management
Much of the recommendations for nonpharmacological management have remained the same. Appendix 4 describes nonpharmacological management that most patients with HF should be encouraged to follow.
Patient education and resources/ tools
Education is important for the patients to manage their symptoms, prevent hospitalizations and prevent progression of their disease. Patients should be educated on self-monitoring and when they should seek medical attention (Table 8) .
Pharmacists should recommend that daily weigh-ins be done in HF patients with fluid retention, poorly controlled congestion or significant renal dysfunction. Patients should weigh themselves daily in the morning, after voiding, to monitor for fluid retention as a sign of worsening HF. Additional resources can be found in Appendix 5. ■
